Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 4
1952 1
1954 2
1955 3
1956 1
1957 1
1959 3
1961 2
1962 2
1964 2
1965 1
1966 3
1968 2
1969 3
1970 3
1971 5
1972 3
1973 7
1974 4
1975 6
1976 3
1977 6
1978 7
1979 11
1980 7
1981 13
1982 13
1983 12
1984 12
1985 12
1986 18
1987 26
1988 15
1989 14
1990 16
1991 18
1992 14
1993 14
1994 18
1995 22
1996 20
1997 27
1998 21
1999 16
2000 24
2001 22
2002 16
2003 23
2004 25
2005 34
2006 33
2007 14
2008 27
2009 27
2010 38
2011 28
2012 36
2013 47
2014 41
2015 39
2016 29
2017 40
2018 39
2019 33
2020 29
2021 35
2022 44
2023 49
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

1,104 results

Results by year

Filters applied: . Clear all
Page 1
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. Among authors: nagao s. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.
Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M, Nagao S, Wainscott DB, Showalter AD, Droz BA, Kobilka TS, Coghlan MP, Willard FS, Kawabe Y, Kobilka BK, Sloop KW. Kawai T, et al. Among authors: nagao s. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29959-29967. doi: 10.1073/pnas.2014879117. Epub 2020 Nov 11. Proc Natl Acad Sci U S A. 2020. PMID: 33177239 Free PMC article.
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P; PAOLA-1/ENGOT-ov25 investigators. Ray-Coquard I, et al. Among authors: nagao s. Ann Oncol. 2023 Aug;34(8):681-692. doi: 10.1016/j.annonc.2023.05.005. Epub 2023 May 19. Ann Oncol. 2023. PMID: 37211045 Free article. Clinical Trial.
Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease.
Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Nakamura T, Asaji K, Mukawa C, Tsukamoto H, Sato T, Oikawa Y, Iwasaki T, Oe Y, Tsukimi T, Fukuda NN, Ho HJ, Nanto-Hara F, Ogura J, Saito R, Nagao S, Ohsaki Y, Shimada S, Suzuki T, Toyohara T, Mishima E, Shima H, Akiyama Y, Akiyama Y, Ichijo M, Matsuhashi T, Matsuo A, Ogata Y, Yang CC, Suzuki C, Breeggemann MC, Heymann J, Shimizu M, Ogawa S, Takahashi N, Suzuki T, Owada Y, Kure S, Mano N, Soga T, Wada T, Kopp JB, Fukuda S, Hozawa A, Yamamoto M, Ito S, Wada J, Tomioka Y, Abe T. Kikuchi K, et al. Among authors: nagao s. Nat Commun. 2019 Apr 23;10(1):1835. doi: 10.1038/s41467-019-09735-4. Nat Commun. 2019. PMID: 31015435 Free PMC article.
[Ⅳ.Endometrial Cancer].
Nagao S. Nagao S. Gan To Kagaku Ryoho. 2020 Feb;47(2):247-251. Gan To Kagaku Ryoho. 2020. PMID: 32381957 Japanese. No abstract available.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: nagao s. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
1,104 results